[go: up one dir, main page]

WO2008109366A3 - Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof Download PDF

Info

Publication number
WO2008109366A3
WO2008109366A3 PCT/US2008/055368 US2008055368W WO2008109366A3 WO 2008109366 A3 WO2008109366 A3 WO 2008109366A3 US 2008055368 W US2008055368 W US 2008055368W WO 2008109366 A3 WO2008109366 A3 WO 2008109366A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
gene expression
inhibiting
acid compounds
mdrna
Prior art date
Application number
PCT/US2008/055368
Other languages
French (fr)
Other versions
WO2008109366A2 (en
WO2008109366A4 (en
Inventor
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Original Assignee
Mdrna Inc
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdrna Inc, Steven C Quay, James Mcswiggen, Narendra K Vaish, Mohammad Ahmadian filed Critical Mdrna Inc
Publication of WO2008109366A2 publication Critical patent/WO2008109366A2/en
Publication of WO2008109366A3 publication Critical patent/WO2008109366A3/en
Publication of WO2008109366A4 publication Critical patent/WO2008109366A4/en
Priority to US12/552,082 priority Critical patent/US20100105134A1/en
Priority to US13/327,545 priority patent/US20130011922A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing CCNDl gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a CCNDl mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine, a nucleoside that is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a CCND 1 gene in a cell or in a subject to treat a CCND 1 -related disease.
PCT/US2008/055368 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof WO2008109366A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/552,082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13/327,545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93494007P 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007P 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US1398207P 2007-12-14 2007-12-14
US61/013,982 2007-12-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055676 Continuation-In-Part WO2008109532A2 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting fas gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055678 Continuation-In-Part WO2008109534A1 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
AU2009212920A Division AU2009212920A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US12/552,082 Continuation-In-Part US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (3)

Publication Number Publication Date
WO2008109366A2 WO2008109366A2 (en) 2008-09-12
WO2008109366A3 true WO2008109366A3 (en) 2008-12-11
WO2008109366A4 WO2008109366A4 (en) 2009-01-29

Family

ID=39720477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055368 WO2008109366A2 (en) 2007-03-02 2008-02-28 Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109366A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049078A1 (en) 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
DE102008033175A1 (en) 2008-07-15 2010-01-21 Merck Patent Gmbh Silica nanoparticles and their use for vaccination
EP3594346A4 (en) * 2017-03-10 2020-12-16 National Center For Child Health And Development ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA
CN111511915A (en) 2018-03-09 2020-08-07 第一三共株式会社 Remedies for glycogen disease type Ia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
WO2008049078A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
WO2008049078A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAMSEN JESPER B. ET AL.: "Improved silencing properties using small internally segmented interfering RNAs", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 35, no. 17, 28 July 2007 (2007-07-28), pages 5886 - 5897, XP002458184, ISSN: 0305-1048 *
FREEMANTLE SARAH J ET AL: "Repression of cyclin D1 as a target for germ cell tumors", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 30, no. 2, February 2007 (2007-02-01), pages 333 - 340, XP002494844, ISSN: 1019-6439 *
HAGERMAN K.R. AND HAGERMAN P.J.: "Helix rigidity of DNA: the meroduplex as an experimental paradigm", JOURNAL OF MOLECULAR BIOLOGY, vol. 260, 1996, pages 207 - 223, XP002484999 *
LEUSCHNER P J F ET AL: "Cleavage of the siRNA passenger strand during RISC assembly in human cells", EMBO REPORTS, vol. 7, no. 3, 1 March 2006 (2006-03-01), pages 314 - 320, XP002467845 *
MARY GRILLO ET AL: "Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 95, no. 2, 1 January 2006 (2006-01-01), pages 185 - 194, XP019274965, ISSN: 1573-7217 *
MILLS JANINE B ET AL: "Origin of the intrinsic rigidity of DNA", NUCLEIC ACIDS RESEARCH,, vol. 32, no. 13, 1 January 2004 (2004-01-01), pages 4055 - 4059, XP002484664 *

Also Published As

Publication number Publication date
WO2008109366A2 (en) 2008-09-12
WO2008109366A4 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
WO2008109460A3 (en) Nucleic acid compounds for inhibiting ctnnb1 gene expression and uses thereof
WO2008109381A3 (en) Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
WO2009029293A3 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
WO2008109516A3 (en) Nucleic acid compounds for inhibiting ras gene expression and uses thereof
WO2008109352A3 (en) Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2010017319A3 (en) Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2008109546A3 (en) Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
WO2008109375A3 (en) Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2008109366A3 (en) Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008109350A3 (en) Nucleic acid compounds for inhibiting il6 gene expression and uses thereof
WO2008109372A3 (en) Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
WO2008109548A3 (en) Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
WO2008109506A8 (en) Nucleic acid compounds for inhibiting jun gene expression and uses thereof
WO2008109487A3 (en) Nucleic acid compounds for inhibiting mme gene expression and uses thereof
WO2008109495A3 (en) Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof
WO2008109532A8 (en) Nucleic acid compounds for inhibiting fas gene expression and uses thereof
WO2008109558A3 (en) Nucleic acid compounds for inhibiting tlr gene expression and uses thereof
WO2008109443A3 (en) Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2011139843A3 (en) Multi-sirna compositions for reducing gene expression
WO2008109364A3 (en) Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731022

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731022

Country of ref document: EP

Kind code of ref document: A2